Deep Piction observed strong, punctate EGFP expression in the lung after intravenous administration of STV-C8.
Public source
Publisher name
Public post
🧬 What if we could design RNA delivery systems that don’t exist in nature? 𝐍𝐞𝐰 𝐢𝐧 𝐍𝐚𝐭𝐮𝐫𝐞: our collaborative work introduces STV-C8, an AI-designed protein as…
Company
Deep Piction
AI-driven & sustainable biotech R&D Towards animal-free innovations
- Industry
- Biotechnology Research
- Location
- Munich, DE
- Company size
- 11–50 employees
About Deep Piction
Transforming Biotech: AI-Driven Cell-Level Imaging for Internal & Partner Drug Development Deep Piction is transforming biotechnological research and drug development with our unique tissue transparency platform and AI algorithms we developed. This proprietary technology generates the highest-resolution images, maps, and information of whole mammalian bodies, including intact human organs, at unparalleled cellular detail. This groundbreaking capability fuels our internal drug development pipeline by enabling unbiased, systems-level investigation of diseases at the cell level. For the very first time, we can develop precision medicine at the cellular level, significantly accelerating discovery and reducing reliance on animal testing. Imagine precisely tracking single CAR T cells to understand their efficacy, or visualizing exactly which cells gene delivery tools are targeting (and which they’re not) within an entire body. Our platform is not just for us; we have already worked with leading pharmaceutical companies that are keen to leverage our technology to gain unprecedented insights, accelerate pipelines, and tackle complex challenges in human health. Powered by advanced deep learning techniques and the world’s largest, highest-quality database of cell-level images, Deep Piction is building the future of precision therapeutics. Join us in unlocking the full potential of AI and cell-level imaging to improve human health and advance scientific discovery.
See moreLatest activity
Latest activity from Deep Piction
3 signals
Research & Knowledge
Deep Piction used generative AI to create 100+ synthetic architectures, with STV-C8 showing remarkable delivery efficiency and programmable cellular targeting.
Research & Knowledge
Deep Piction introduced STV-C8, an AI-designed protein assembly engineered from the bottom up for RNA delivery.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
ScienTek
ScienTek STV-C8 primarily induced RNA expression in the lungs in mice without immunological or toxic side effects.
Research & Knowledge
Dyno Therapeutics
Dyno Therapeutics has used large-scale in vivo data paired with AI models since 2018 to engineer AAV capsids for therapeutic payloads.
Research & Knowledge
Inceptive
Inceptive used its AI models to design anti-CD19 CAR-expressing mRNA sequences, testing five designs in humanized mice against an industry-leading commercial sequence.
Research & Knowledge
Kantify
Kantify validated Sapian's ability to generalize across different target classes, both in vitro and in vivo, from human health to crop science.
Research & Knowledge
Raina Biosciences